Evaluation of elastography combined with serological indexes for hepatic fibrosis in patients with chronic hepatitis B

Table 1 Comparison of clinical data in the two groups

	Hepatic fibrosis group (n = 245)	Control group (n = 93)	t/χ2 value	P value
Sex (male/%)	136/55.51	45/48.39	1.375	0.241
Age	40.31 ± 10.47	37.82 ± 13.72	1.785	0.075
SWV (m/s)	3.02 ± 0.80	1.52 ± 0.62	16.310	0.000
ALT (U/L)	52.23 ± 26.02	46.87 ± 87.45	1.487	0.138
AST (U/L)	41.12 ± 12.72	36.14 ± 14.52	1.607	0.109
AST/ALT	0.93 ± 0.41	0.74 ± 0.23	4.221	0.000
PLT (109/L)	184.02 ± 02.21	192.37 ± 37.42	1.220	0.223
TBIL (μmol/L)	19.83 ± 9.83	18.75 ± 8.72	1.570	0.117
HA (μg/L)	113.24 ± 24.78	63.23 ± 23.54	15.748	0.000
LN (μg/L)	36.21 ± 21.34	34.21 ± 10.28	1.485	0.139
CIV (μg/L)	33.28 ± 28.20	20.89 ± 9.56	4.144	0.000
PIIINP (μg/L)	36.29 ± 29.45	32.87 ± 2.32	1.100	0.272
APRI	0.85 ± 0.61	0.62 ± 0.52	3.219	0.001
FIB-4	1.63 ± 0.89	1.17 ± 0.62	4.578	0.000

SWV: Shear wave velocity; ALT: Alanine aminotransferase; AST: Aspartate transaminase; PLT: Blood platelet; TBIL: Total bilirubin; HA: Hyaluronic acid; LN: Laminin; CIV: Type IV collagen; PIIINP: Type III procollagen; APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis index based on the 4 factor.